Enorna provides research-grade LNP encapsulation services built on deep expertise in lipid design, including both commercial and novel ionizable lipids.
Utilizing our proprietary library of cationic lipid molecules, we support formulation screening to identify high-efficiency, low-toxicity, and tissue-specific delivery systems. Our platform delivers comprehensive support for preclinical in vitro and in vivo studies, accelerating the development of innovative nucleic acid therapeutics.
•Customizable purification strategies tailored to diverse application needs
•GMP‑aligned microfluidic platform ensuring high batch‑to‑batch consistency
•Flexible and comprehensive testing panels that guarantee delivery system quality
•Commercial lipids (e.g. SM-102, etc.)
•Enorna-recommended foumulations (clear IP ownership)
•Client-supplied Lipids
•GLP-grade batches up to 300 mL; larger-scale production available through CDMO services
•Seamless transition from preclinical research to clinical-stage development
LNP CDMO Solutions1) Commercial Lipids (e.g. SM-102, etc.)
2) Enorna-Recommended Foumulations (Clear IP Ownership)
3) Client-Supplied Lipids
1) Commercial Lipids (e.g. SM-102, etc.)
2) Enorna-Recommended Foumulations (Clear IP Ownership)
3) Client-Supplied Lipids
a) RNA-LNP Product
b) ROA
a) RNA-LNP Product
b) ROA
Reach Out Today
Contact us
<4k nt: ≥75%
>4k nt: Reported Value
MC3-LNP 80-110 nm
SM102-LNP 65-125 nm
LP01-LNP 65-125 nm
ALC0315-LNP 50-100 nm
Y
N
Optional
Tel. +86 18961517608
E-mail. bd@enorna.com
Address.
63 Keji Avenue,
Bldg. 6, Fl. 6,
Yixing, Jiangsu, China
